![]() |
Effect of tibolone on the survival of early stage cervical adenocarcinoma patients
Seung-Ho Lee, Yoon-Jin Cho, Kyung-Joo Cho, Mee-Hyang Ko, Sun-Young Jung, Seung-Joo Chon, So-Yi Lim, Kwang-Beom Lee
Obstet Gynecol Sci. 2018;61(5):584-589. Published online 2018 Aug 7 DOI: https://doi.org/10.5468/ogs.2018.61.5.584
|
Citations to this article as recorded by
Hormone Replacement Therapy in Post-Menopause Hormone-Dependent Gynecological Cancer Patients: A Narrative Review
Paola Villa, Valentina Elisabetta Bounous, Inbal Dona Amar, Federica Bernardini, Margherita Giorgi, Daniela Attianese, Annamaria Ferrero, Marika D’Oria, Giovanni Scambia
Journal of Clinical Medicine.2024; 13(5): 1443. CrossRef Systemic hormone therapy after breast and gynecological cancers: an Italian expert group consensus opinion
Angelo Cagnacci, Paola Villa, Giuseppina Paola Grassi, Nicoletta Biglia, Marco Gambacciani, Costantino Di Carlo, Francesca Nocera, Salvatore Caruso, Angelamaria Becorpi, Stefano Lello, Anna Maria Paoletti
Climacteric.2024; : 1. CrossRef Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma
A Richardson, L Watson, M Persic, A Phillips
Post Reproductive Health.2021; 27(3): 167. CrossRef Hormone replacement therapy following treatment of gynaecological malignancies
Alison Richardson, Julie Ayres, Mike Cust, Andrew Phillips
The Obstetrician & Gynaecologist.2019; 21(4): 291. CrossRef
|